The agency deemed the devices substantially equivalent, allowing Shenzhen Mericonn Technology to market four mesh nebulizer models in the U.S.
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Shenzhen Mericonn Technology Co., Ltd. for four of its mesh nebulizer models. The decision, dated September 18, 2026, designates the Mesh Nebulizer (UN204), Mesh Nebulizer (UN205), Mesh Nebulizer (UN209), and Mesh Nebulizer (UN210) as substantially equivalent to a predicate device, enabling their legal marketing in the United States.
This Traditional 510(k) clearance falls under Product Code CAF, categorizing the devices as Class II and regulated under 21 CFR 868.5630 for Nebulizers. The advisory committee responsible for this review was Anesthesiology. As is standard for 510(k) clearances, the FDA did not conduct a de novo review, but rather assessed the devices against existing legally marketed products.
Device Function and Market Context
Nebulizers are medical devices used to administer medication in the form of a mist inhaled into the lungs. Mesh nebulizers, specifically, utilize a vibrating mesh or aperture plate to generate fine aerosol particles from liquid medication. This technology is often favored for its portability, efficiency, and quiet operation compared to traditional jet nebulizers.
The market for nebulizer systems is established, with numerous manufacturers offering various device types. Shenzhen Mericonn Technology's entry with these four models expands the available options within the mesh nebulizer segment. Specific clinical efficacy data, target patient populations, or commercial launch details for these particular models have not been disclosed by the company at this time.
The clearance underscores the FDA's continued review of new and existing medical device technologies to ensure market safety and efficacy standards are met.
Regulatory Pathway and Future Implications
Receiving 510(k) clearance is a critical step for medical device manufacturers seeking to enter or expand within the U.S. market. For Shenzhen Mericonn Technology, this clearance permits the commercial distribution of its UN204, UN205, UN209, and UN210 mesh nebulizers. The specific predicate device used for comparison has not been publicly identified in the summary document. Further details regarding the devices’ technical specifications, intended use, and indications for use would typically be found in the full 510(k) submission.
Companies often leverage such clearances to broaden their product portfolios and address specific patient needs or market niches. The competitive landscape for respiratory care devices necessitates ongoing innovation and regulatory compliance. Shenzhen Mericonn's strategic positioning within this market will likely depend on product differentiation, distribution channels, and post-market surveillance activities, none of which have been publicly detailed.
